Liquidia reports 2024 revenue down to $14.0 million and net loss of $130.4 million
Liquidia reported full-year 2024 revenue of $14.0 million, down from $17.5 million, and a net loss of $130.4 million, or $1.66 per share, versus a net loss of $78.5 million, or $1.21 per share, in 2023. Cash and cash equivalents rose to $176.5 million at year-end, and the company amended its HCRx financing agreement to provide up to an additional $100 million, with $25.0 million received at closing. Shareholders face wider losses and lower revenue, while the company awaits possible final FDA approval of YUTREPIA after regulatory exclusivity expires on May 23, 2025.
Key points
- Revenue fell to $14.0 million from $17.5 million, mainly due to lower sales quantities tied to limited availability of pumps for Treprostinil Injection.
- General and administrative expenses rose to $81.6 million from $44.7 million; research and development expenses rose to $47.8 million from $43.2 million.
- Net loss was $130.4 million, or $1.66 per share, compared with $78.5 million, or $1.21 per share, in 2023.
- The HCRx amendment provides up to $100 million in three tranches; Liquidia received $25.0 million at closing.
The filing
Written by AI on Nov 8, 2026, 1:01 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 19, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.